NASDAQ:OPNTOpiant Pharmaceuticals Stock Price, Forecast & News

Opiant Pharmaceuticals' stock was trading at $10.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OPNT shares have increased by 7.8% and is now trading at $11.70. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Opiant Pharmaceuticals.

Opiant Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Opiant Pharmaceuticals.

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) announced its quarterly earnings results on Tuesday, May, 12th. The technology company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.21. The technology company had revenue of $4.28 million for the quarter, compared to analyst estimates of $4.63 million. Opiant Pharmaceuticals had a return on equity of 3.27% and a net margin of 29.58%. View Opiant Pharmaceuticals' earnings history.

1 brokers have issued twelve-month price targets for Opiant Pharmaceuticals' shares. Their forecasts range from $42.00 to $42.00. On average, they anticipate Opiant Pharmaceuticals' share price to reach $42.00 in the next twelve months. This suggests a possible upside of 259.0% from the stock's current price. View analysts' price targets for Opiant Pharmaceuticals.

Press coverage about OPNT stock has trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Opiant Pharmaceuticals earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned press coverage about the technology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutOpiant Pharmaceuticals.

Opiant Pharmaceuticals saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 3,200 shares, a decline of 5.9% from the April 15th total of 3,400 shares. Based on an average trading volume of 18,400 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are sold short. View Opiant Pharmaceuticals' Current Options Chain.

Some companies that are related to Opiant Pharmaceuticals include Rubicon Minerals (RBYCF), Fission Uranium (FCUUF), Mountain Province Diamonds (MPVDF), Amerigo Resources (ARREF), Dakota Territory Resource (DTRC), Atlatsa Resources (ATLRF), Pacific Booker Minerals (PBMLF), Santa Fe Gold (SFEG), Bullfrog Gold (BFGC), US Gold (USAU), Silver Bull Resources (SVBL), Avalon Advanced Materials (AVLNF), Westwater Resources (WWR), Quantum Materials (QTMM) and Quaterra Resources (QTRRF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include AcelRx Pharmaceuticals (ACRX), Cara Therapeutics (CARA), Synchrony Financial (SYF), Vodafone Group (VOD), Cyberark Software (CYBR), AT&T (T), Corbus Pharmaceuticals (CRBP), Cronos Group (CRON), Vodafone Group (VOD) and Agenus (AGEN).

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

Opiant Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (8.95%), Fondren Management LP (7.38%), BlackRock Inc. (0.49%), Mesirow Financial Investment Management Inc. (0.48%), Alambic Investment Management L.P. (0.36%) and Wedge Capital Management L L P NC (0.30%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Gabrielle Alison Silver, Michael Sinclair, Phil Skolnick and Roger Crystal. View institutional ownership trends for Opiant Pharmaceuticals.

OPNT stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, and BlackRock Inc.. Company insiders that have sold Opiant Pharmaceuticals company stock in the last year include Michael Sinclair, and Phil Skolnick. View insider buying and selling activity for Opiant Pharmaceuticals.

OPNT stock was purchased by a variety of institutional investors in the last quarter, including Fondren Management LP, Stonepine Capital Management LLC, Mesirow Financial Investment Management Inc., Alambic Investment Management L.P., Acadian Asset Management LLC, Advisor Group Holdings Inc., and Morgan Stanley. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall, David D O'toole, and Gabrielle Alison Silver. View insider buying and selling activity for Opiant Pharmaceuticals.

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OPNT stock can currently be purchased for approximately $11.70.

Opiant Pharmaceuticals has a market capitalization of $49.84 million and generates $40.52 million in revenue each year. The technology company earns $11.59 million in net income (profit) each year or $0.20 on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.

The official website for Opiant Pharmaceuticals is www.opiant.com.

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]